U.S. Other Utilities Stock News

Pathward Financial (CASH) gave investors fresh numbers to assess with its latest quarterly earnings, showing lower net interest income but higher earnings per share and continued progress in tax services and commercial finance. See our latest analysis for Pathward Financial. The recent earnings release appears to have reinforced positive sentiment, with the 30 day share price return of 7.94% and 90 day share price return of 23.29% contributing to a 1 year total shareholder return of 25.09%...

Why Nutanix is Back on Investor Radar Recent commentary around Nutanix (NTNX) has zeroed in on its high gross margin of 87.1%, strong free cash flow, and cash-heavy balance sheet, drawing extra attention ahead of the upcoming earnings release. For you as an investor, this mix of profitability metrics and an earnings catalyst raises practical questions about how Nutanix’s business model and current valuation might fit into a broader portfolio focused on software and cloud exposure. See our...

The United States market has shown robust performance with a 1.7% increase over the last week and a remarkable 34% rise over the past year, while earnings are anticipated to grow by 16% annually in the coming years. In this thriving environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation potential and scalability to capitalize on these favorable conditions.

Over the last 7 days, the United States market has risen by 1.7%, contributing to a remarkable 34% increase over the past year, with earnings anticipated to grow by 16% annually in the coming years. In such a thriving environment, identifying stocks that may be priced below their estimated value can present compelling opportunities for investors seeking potential growth and value.

Westlake (WLK) is back in focus after two meaningful updates: appointing Jonathan H. Baksht as incoming Chief Financial Officer and agreeing to a US$67 million settlement in the PVC Pipe Antitrust Litigation. See our latest analysis for Westlake. At a share price of US$114.28, Westlake has seen a 31.73% 90 day share price return and a 54.12% year to date share price return, while the 1 year total shareholder return sits at 26.95%. This suggests momentum has been building as investors weigh...

The United States market has shown positive momentum, with a 1.7% increase over the last week and a substantial 34% rise over the past year, alongside an anticipated annual earnings growth of 16%. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, aligning well with current market trends.

Earlier this month, Ollie's Bargain Outlet Holdings announced plans to open 75 new stores in fiscal 2026, expanding toward an analyst-forecast footprint of about 1,300 locations over the next few years. The expansion plans arrive as investors question how effectively the retailer can handle operational challenges and current valuation risks while scaling the business. We’ll now examine how Ollie’s aggressive 2026 store expansion plans may reshape its previously optimistic investment...

For investors considering whether Ternium at around US$43.21 offers value or is already fully priced, this article breaks down what the current share price may be implying about the company. The stock has returned 1.2% over the past week, 12.8% over the past month, 10.4% year to date, and 64.9% over the last year. These figures provide useful context before weighing up what you are paying today. Recent coverage of Ternium has focused on its role in the broader metals and materials sector and...

The market has climbed 1.7% in the last 7 days and an impressive 34% over the past year, with earnings forecasted to grow by 16% annually. Investing in penny stocks—typically associated with smaller or newer companies—can still open doors to growth opportunities, especially when these stocks are supported by strong financial health. This article explores several promising penny stocks that combine balance sheet strength with long-term potential for investors seeking underappreciated growth...

NOV (NOV) continues to attract attention after recent share price moves, with the stock closing at US$19.77 and showing positive total returns over the month, past 3 months, year to date, and past year. See our latest analysis for NOV. The recent 7 day share price return of 3.94% and 30 day share price return of 2.54% sit against a much stronger year to date share price return of 20.48% and 1 year total shareholder return of 71.05%. This suggests that momentum has been building over the...

NRG Energy (NRG) has been active in the debt markets, completing several large secured and unsecured note offerings due 2031, 2034, and 2036 that are tied to refinancing existing obligations and funding a subsidiary tender offer. See our latest analysis for NRG Energy. Despite the recent debt offerings and the latest quarterly dividend declaration, NRG Energy’s 7 day share price return of an 11.19% decline and year to date share price return of a 9.97% decline contrast with a strong 1 year...

Why Cigna Group Is On Investors’ Radar Today Cigna Group (CI) is back in focus after recent trading left the shares around $274.70, with mixed short term performance that includes a 1 day decline and gains over the past week and month. For investors tracking longer trends, the stock shows a negative total return over the past year alongside positive 3 year and 5 year total returns, which may encourage closer attention to how the business is currently positioned. See our latest analysis for...

Kilroy Realty (KRC) is back in focus after management reported faster leasing activity, completed the second phase of Kilroy Oyster Point in South San Francisco, and outlined plans to reshape its future development pipeline. See our latest analysis for Kilroy Realty. These updates come after a mixed share price picture, with a 10.31% 1 month share price return and 3.97% 7 day share price return contrasting with a 16.70% year to date decline. The 3 year total shareholder return of 31.37%...

The United States market has shown robust performance, rising 1.7% over the past week and climbing 34% in the last year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying lesser-known stocks with strong growth potential can offer unique opportunities for investors seeking to capitalize on emerging trends.

ACI Worldwide recently expanded its cloud-native ACI Connetic platform, now connecting eight major U.S. payment networks including Fedwire, CHIPS, Swift, The Clearing House RTP, Zelle and FedNow, with Nacha ACH connectivity expected next year, while also integrating stablecoin and tokenized-deposit capabilities on a single SaaS infrastructure. A key differentiator is ACI Connetic’s embedded fraud and financial crime detection across payment rails, designed to meet evolving rules such as...

Regulatory tailwind and clinic collaboration reshape the COMPASS Pathways story COMPASS Pathways (NasdaqGS:CMPS) is in focus after a new executive order to accelerate psychedelic medicine approvals, paired with fresh clinical and delivery partnerships around its COMP360 psilocybin therapy program. See our latest analysis for COMPASS Pathways. The executive order and positive COMP360 trial updates have arrived alongside intense share price swings, with a 7 day share price return of 46.8% and a...

Spotify snapshot and recent performance Spotify Technology (NYSE:SPOT) continues to draw investor attention after recent trading, with the share price closing at $522.88 and returns showing mixed signals across the past week, month, past 3 months and year to date. See our latest analysis for Spotify Technology. Viewed over a longer stretch, the recent 6.2% 30 day share price return sits against a 9.1% year to date share price decline and a 292.8% three year total shareholder return. This...

Earlier this year, Lantheus Holdings secured FDA approval for its PYLARIFY TruVu imaging agent and is awaiting a separate FDA decision on its LNTH-2501 diagnostic kit, expected by late June. At the same time, projections of a 6.3% sales decline and pressure on operating margins highlight how rising costs and softer demand may temper the impact of these new products. We’ll now examine how the PYLARIFY TruVu approval, alongside projected sales headwinds, reshapes Lantheus Holdings’ existing...

If you are wondering whether DocuSign at around US$47.52 is a bargain or a value trap, the answer starts with understanding what the market might be pricing in today. The stock has recently returned 1.5% over the last 7 days, while being down 2.6% over 30 days, 26.7% year to date, 39.1% over 1 year, and 79.5% over 5 years, which gives important context before looking at any valuation numbers. These returns keep DocuSign on many investors' watchlists, as the long term share price record sits...

Investors may be wondering if Clorox at around US$96.85 is pricing in too much pessimism, or if the market is overlooking its potential value. The share price has retreated recently, with a 5.9% decline over 7 days, 8.5% over 30 days, 4.0% year to date and 27.2% over the last year. The 3 year and 5 year returns sit at 33.8% and 38.0% declines, respectively. These moves have kept Clorox on many investors' watchlists, as the stock's pullback is prompting questions about whether sentiment has...

This article examines whether Science Applications International might represent value at its current share price by walking through what the numbers are actually indicating about the stock. With a share price of US$95.71 and a 16.5% gain over five years, recent returns have been softer, with the stock down 0.5% over the past week, 1.2% over the past month, 5.4% year to date and 19.0% over the last year. Recent headlines around Science Applications International have focused on its role as a...

Event driven overview of Crown Holdings Crown Holdings (CCK) has recently drawn investor attention after a period where the stock showed mixed short term moves, including a small decline over the past week and a modest gain over the past month. Against this share price backdrop, readers are revisiting the company’s fundamentals, including its US$12.4b in revenue, US$738 million in net income, and its role in global beverage and transit packaging markets. See our latest analysis for Crown...

Earlier this week, Hims & Hers Health said clinicians on its platform can now prescribe Eli Lilly GLP-1 weight loss drugs, which will be filled through LillyDirect, adding to existing access to Novo Nordisk’s Wegovy and other branded treatments. This move strengthens Hims & Hers’ role as a prescribing hub in the fast-growing GLP-1 care ecosystem by plugging directly into major drugmakers’ distribution channels. Next, we’ll examine how integrating Eli Lilly’s GLP-1 treatments through...

If you are wondering whether Lam Research shares still offer value after a strong run, or if you are turning up late to the party, this breakdown can help you frame the risk and reward trade off more clearly. The stock closed at US$265.55 and has posted returns of 0.1% over 7 days, 13.8% over 30 days, 43.5% year to date, 300.9% over 1 year, 449.5% over 3 years and 339.0% over 5 years. Recent headlines around Lam Research have focused on its role in semiconductor equipment, its exposure to...